| Characteristics | Patients (N = 132) | Purpose of CV-port implantation | p-value | |
| CC group (N = 79) | PC group (N = 53) | |||
| Sex, N (%) |
|
|
|
|
| Male | 90 | 53 (58.9) | 37 (41.1) |
|
| Female | 42 | 26 (61.9) | 16 (38.1) | 0.849 |
| Age (years) |
|
|
|
|
| Median (range) | 67 (36 - 87) | 66 (36 - 85) | 67.5 (42 - 87) | 0.232 |
| Histology, N (%) |
|
|
|
|
| SCLC | 35 | 27 (77.1) | 8 (22.9) |
|
| NSCLC | 97 | 52 (53.6) | 45 (46.4) | 0.016 |
| ECOG PS, N (%) |
|
|
|
|
| 0 - 1 | 59 | 58 (98.3) | 1 (1.7) |
|
| 2 - 3 | 51 | 20 (39.2) | 31 (60.8) |
|
| 4 | 22 | 1 (4.5) | 21 (95.5) | <0.0001 |
| Stage, N (%) |
|
|
|
|
| I-II | 5 | 4 (80.0) | 1 (20.0) |
|
| IIIA-B | 14 | 11 (78.6) | 3 (21.4) |
|
| IV | 113 | 64 (56.6) | 49 (43.4) | 0.243 |
| Insertion site of the CV-port, N (%) |
|
|
|
|
| RSV | 91 | 60 (65.9) | 31 (34.1) |
|
| LSV | 23 | 13 (56.5) | 10 (43.5) |
|
| RIV | 16 | 5 (31.3) | 11 (68.7) |
|
| LIV | 1 | 0 (0.0) | 1 (100.0) |
|
| RIJV | 1 | 1 (100.0) | 0 (0.0) |
|
| Preimplantation chemotherapy |
|
|
|
|
| Number of regimens, median (range) | 2 (0 - 7) | 2 (0 - 7) | 2 (0 - 6) | 0.060 |
| Number of cycles, median (range) | 5 (0 - 65) | 8 (0 - 65) | 4 (0 - 25) | 0.006 |